Ellie Eunkyung Im
Known title: Chief Medical OfficerCIK: 0002075219
Associated companies
Transaction History
| CBIO | ▼ Sell | Open Market | 623 | $11K | 9/16/2026 | View on chart |
| CBIO | ▼ Sell | Open Market | 1,219 | $22K | 6/22/2026 | View on chart |
| CBIO | ▲ Buy | Grant | 16,298 | — | 12/15/2025 | View on chart |
| CBIO | ▲ Buy | Grant | 5,000 | — | 12/15/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
CBIO Announces New Clinical Trial Milestones for CR-001
Crescent Biopharma said it is enrolling patients in the standard‑of‑care chemotherapy arms of its global Phase 1/2 ASCEND trial for CR‑001, a PD‑1 × VEGF bispecific antibody. The company also began additional antibody‑drug‑conjugate combination studies with CR‑001. These steps indicate progress in the drug’s development and broaden its potential clinical applications.
CBIO Announces New Clinical Trial Milestones for CR-001. Crescent Biopharma said it is enrolling patients in the standard‑of‑care chemotherapy arms of its global Phase 1/2 ASCEND trial for CR‑001, a PD‑1 × VEGF bispecific antibody. The company also began additional antibody‑drug‑conjugate combination studies with CR‑001. These steps indicate progress in the drug’s development and broaden its potential clinical applications.